Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Most relevant news about GILEAD SCIENCES, INC.
04:02aGILEAD SCIENCES : Presents Survey Findings on PrEP Access and Utilization in the..
BU
07/06GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
AQ
07/06GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
AQ
07/06GILEAD SCIENCES : European Commission Grants Conditional Marketing Authorization..
AQ
07/06GILEAD SCIENCES : New Findings on Gilead's Biktarvy Presented at AIDS 2020, Virt..
AQ
07/04GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
BU
07/04NEW FINDINGS ON GILEAD'S BIKTARVY® P : Virtual Include Positive Switch Data in O..
BU
07/03GILEAD SCIENCES : COVID-19 antiviral remdesivir gets conditional EU clearance
RE
07/03GILEAD SCIENCES : European Commission Authorizes Gilead's Marketing of Remdesivi..
DJ
07/03GILEAD SCIENCES : European Commission Grants Conditional Marketing Authorization..
BU
07/02GILEAD SCIENCES : Demonstrates Commitment to Scientific Innovation in HIV with N..
AQ
07/01GILEAD SCIENCES DEMONSTRATES COMMITM : Virtual
BU
07/01GILEAD SCIENCES : South Korea to start talks on COVID-19 drug remdesivir purchas..
RE
06/30GILEAD SCIENCES : An Open Letter from Daniel O'Day, chairman and CEO, Gilead Sci..
AQ
06/29GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient --..
DJ
More most relevant news
All news about GILEAD SCIENCES, INC.
04:02aGILEAD SCIENCES : Presents Survey Findings on PrEP Access and Utilization in the..
BU
07/07GSK to develop plant-based COVID-19 vaccine with Canada's Medicago
RE
07/06Precision BioSciences Says Gilead Ends Hepatitis B Collaboration
DJ
07/06GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
AQ
07/06GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
AQ
07/06GILEAD SCIENCES : European Commission Grants Conditional Marketing Authorization..
AQ
07/06GILEAD SCIENCES : New Findings on Gilead's Biktarvy Presented at AIDS 2020, Virt..
AQ
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
07/05Correction to Poor Performance of Health-Care Stocks Article
DJ
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
More news
News in other languages on GILEAD SCIENCES, INC.
04:02aGILEAD SCIENCES : Presents Survey Findings on PrEP Access and Utilization in the..
07/07GSK to develop plant-based COVID-19 vaccine with Canada's Medicago
07/07AVIS D'ANALYSTES DU JOUR : Air Liquide, Euronext, Getlink, Puma, Hugo Boss, Netf..
07/07Mise en orbite des valeurs technologiques
07/06EUROPE : Les marchés européens relancés par la Chine et "insensibles" au Covid-1..
07/06STOCK MARKET PARIS : Paris insensible à l'évolution sanitaire
07/06GILEAD : en hausse, un broker en soutien
07/06GILEAD : Jefferies reste à l'achat
07/06USA: Les valeurs à suivre à Wall Street
07/06Precision BioSciences Says Gilead Ends Hepatitis B Collaboration
Analyst Recommendations on GILEAD SCIENCES, INC.
06/15GILEAD SCIENCES : DZ Bank reaffirms its Buy rating
MD
More recommendations
Press releases
04:02aGILEAD SCIENCES : Presents Survey Findings on PrEP Access and Utilization in the..
BU
07/06GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
AQ
07/06GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
AQ
07/06GILEAD SCIENCES : European Commission Grants Conditional Marketing Authorization..
AQ
07/06GILEAD SCIENCES : New Findings on Gilead's Biktarvy Presented at AIDS 2020, Virt..
AQ
More press releases
Upcoming event on GILEAD SCIENCES, INC.